Investor Relations
Merrion Pharmaceuticals plc (‘Merrion’) is a speciality pharmaceutical company with operations in Ireland and the United States and is focused on the development of improved oral dosage forms of drugs with poor bioavailability. Merrion, founded in 2003, was formed to acquire a range of assets from Elan Corporation following the announcement that it was re-organising to focus on key therapeutic areas and was electing to dispose of its drug delivery businesses. Merrion is currently developing improved formulations of known drugs, which will allow: (i) the drug to be administered orally when previously it was in injectable form; and/or (ii) improve the bioavailability of an existing oral formulation. The company is developing these enhanced drug profiles using its patented drug delivery platforms GIPET and GIRES. It is also looking to develop the platforms as drug delivery options for companies bringing new drugs to the market.
Recent Releases
Mar 8, 2010
Merrion Pharmaceuticals Plc Announces Preliminary Results for the year ended 31 Dec 2009
Mar 2, 2010
Merrion Pharmaceuticals plc announces issuance of key United States Patent, 2nd March 2010
Recent Company Presentations
Sep 21, 2009
Jonathan O'Connell, CFO, Presentation at UBS Global Life Science Conference, New York
Feb 18, 2009
Merrion CEO, John Lynch, Addresses Biobusiness Conference, Geneva, Switzerland.
Oct 9, 2008
Merrion Pharmaceuticals Interim Report June 2008
Sep 23, 2008
Merrion Pharmaceuticals presentation at Sachs Associates, 8th Annual Biotech in Europe Investor Forum
Jun 24, 2008
Merrion Pharmaceuticals Plc Presentation at the Piper Jaffray Europe Conference
Jan 8, 2008
Making Medicines Better
